Indication
Stage IV chronic lymphocytic leukemia
9 clinical trials
10 products
14 drugs
Clinical trial
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
TafasitamabDrug
lenalidomideClinical trial
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)Status: Active (not recruiting), Estimated PCD: 2018-08-07
Product
BendamustineProduct
IbrutinibDrug
VarlilumabClinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell TransplantStatus: Completed, Estimated PCD: 2024-02-02
Clinical trial
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline TherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-21
Clinical trial
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)Status: Terminated, Estimated PCD: 2012-12-19
Drug
rituximabDrug
tacrolimusProduct
Anti-thymocyte globulinDrug
cyclophosphamideProduct
FludarabineDrug
busulfanProduct
Immunosuppressive therapyClinical trial
Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaStatus: Completed, Estimated PCD: 2015-07-01
Drug
TisagenlecleucelClinical trial
Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-07-29
Drug
etoposideDrug
prednisoneDrug
VincristineProduct
DoxorubicinClinical trial
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic LeukemiaStatus: Completed, Estimated PCD: 2014-12-01
Drug
fludarabineClinical trial
A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2015-08-17
Drug
alemtuzumabProduct
ofatumumab